Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2016

Open Access 01-12-2016 | Research

Brazilian multicenter study for the evaluation of patients’ satisfaction of blood glucose self-monitoring with BGStar® blood glucose meter in insulinized patients with diabetes mellitus type 1 and 2

Author: Miguel Nasser Hissa

Published in: Diabetology & Metabolic Syndrome | Issue 1/2016

Login to get access

Abstract

Background

Diabetes mellitus (DM) is considered a global epidemic, and patient self-management education and support are critical in preventing and reducing the risk of complications. Self-monitoring of blood glucose (SMBG) is essential for care of individuals with DM, helping patients to achieve and maintain target blood glucose levels. The purpose of this study is to compare the satisfaction of insulinized DM patients on SMBG with use of investigational blood glucose meter (BGM) versus their routine device.

Methods

A national, multicenter, open-label, phase 4 study was conducted on patients with type 1 or 2 DM under insulin therapy regimen, who were asked to use investigational BGM instead of their usual BGM device. The study was performed in 12 centers in Brazil for 12 weeks, with an extension period of 12 weeks. The primary endpoint was to measure the variation on the patients’ level of satisfaction with investigational versus routine BGM, between visits, using a Visual Analogue Scale (VAS). Secondary endpoints addressed handling aspects, satisfaction, adherence and level of functionality and safety of investigational BGM.

Results

The study included 292 patients (36.6 % DM1 and 63.4 % DM2), mean age 50.9 years old (±17.3 years), 57.5 % females. There was statistically significant improvement in global satisfaction with investigational BGM compared with routine BGM according to VAS [mean VAS score raised from 78.8 mm (SD = 18.0) to 90.8 mm (SD = 12.2) between visits]. After 12 weeks, level of satisfaction with investigational BGM according to questionnaires was superior to routine BGM regardless of age group (p < 0.001), type of DM (p < 0.001) or insulin regimen (p < 0.001). Investigational BGM was also regarded as safe, with 10 patients (3.4 %) reporting a total of 13 adverse events during the study.

Conclusions

Levels of satisfaction during SMBG were higher with use of investigational BGM and the device was deemed safe and easy to handle.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization WHO. Global status report on noncommunicable diseases. Geneva: WHO; 2014. World Health Organization WHO. Global status report on noncommunicable diseases. Geneva: WHO; 2014.
2.
go back to reference World Health Organization WHO. Global health estimates: deaths by cause, age, sex and country, 2000–2012. Geneva: WHO; 2014. World Health Organization WHO. Global health estimates: deaths by cause, age, sex and country, 2000–2012. Geneva: WHO; 2014.
3.
go back to reference Pfutzner A, Mitri M, Musholt PB, Sachsenheimer D, Borchert M, Yap A, et al. Clinical assessment of the accuracy of blood glucose measurement devices. Curr Med Res Opin. 2012;28(4):525–31.CrossRefPubMed Pfutzner A, Mitri M, Musholt PB, Sachsenheimer D, Borchert M, Yap A, et al. Clinical assessment of the accuracy of blood glucose measurement devices. Curr Med Res Opin. 2012;28(4):525–31.CrossRefPubMed
4.
go back to reference American Diabetes Association ADA. Standards of medical care in diabetes. Diabetes Care. 2015;38(Supp 1):S1–93. American Diabetes Association ADA. Standards of medical care in diabetes. Diabetes Care. 2015;38(Supp 1):S1–93.
5.
go back to reference Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68.CrossRefPubMed Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68.CrossRefPubMed
6.
go back to reference IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–93.CrossRef IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–93.CrossRef
7.
go back to reference Evans JMM, Newton RW, Ruta DA, MacDonald TM, Stevensson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319:83–6.CrossRefPubMedPubMedCentral Evans JMM, Newton RW, Ruta DA, MacDonald TM, Stevensson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319:83–6.CrossRefPubMedPubMedCentral
8.
go back to reference Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the auto-surveillance intervention active (ASIA) study. Diabetes Metab. 2003;29(6):587–94.CrossRefPubMed Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the auto-surveillance intervention active (ASIA) study. Diabetes Metab. 2003;29(6):587–94.CrossRefPubMed
9.
go back to reference Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Cavaliere D, Di Nardo B, et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care. 2001;24(11):1870–7.CrossRefPubMed Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Cavaliere D, Di Nardo B, et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care. 2001;24(11):1870–7.CrossRefPubMed
10.
go back to reference Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the structured testing program study. Diabetes Care. 2011;34(2):262–7.CrossRefPubMedPubMedCentral Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the structured testing program study. Diabetes Care. 2011;34(2):262–7.CrossRefPubMedPubMedCentral
11.
go back to reference Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess. 2009;13(15):1–50 (iii–iv, ix–xi).CrossRef Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess. 2009;13(15):1–50 (iii–iv, ix–xi).CrossRef
12.
go back to reference Gubitosi-Klug RA. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37(1):44–9.CrossRefPubMed Gubitosi-Klug RA. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37(1):44–9.CrossRefPubMed
13.
go back to reference DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746.CrossRefPubMedCentral DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746.CrossRefPubMedCentral
14.
go back to reference Karter AJ, Ackerson LM, Darbinian JA, D’Agostino RB Jr, Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111(1):1–9.CrossRefPubMed Karter AJ, Ackerson LM, Darbinian JA, D’Agostino RB Jr, Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111(1):1–9.CrossRefPubMed
15.
go back to reference Canadian Diabetes Association CDA. Self-monitoring of blood glucose in people with type 2 diabetes: Canadian Diabetes Association briefing document for healthcare providers. Can J Diabetes. 2011;35:317–9.CrossRef Canadian Diabetes Association CDA. Self-monitoring of blood glucose in people with type 2 diabetes: Canadian Diabetes Association briefing document for healthcare providers. Can J Diabetes. 2011;35:317–9.CrossRef
16.
go back to reference Ramljak S, Musholt PB, Schipper C, Flacke F, Sieber J, Borchert M, et al. The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Expert Opin Med Diagn. 2013;7(6):511–6.CrossRefPubMed Ramljak S, Musholt PB, Schipper C, Flacke F, Sieber J, Borchert M, et al. The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Expert Opin Med Diagn. 2013;7(6):511–6.CrossRefPubMed
Metadata
Title
Brazilian multicenter study for the evaluation of patients’ satisfaction of blood glucose self-monitoring with BGStar® blood glucose meter in insulinized patients with diabetes mellitus type 1 and 2
Author
Miguel Nasser Hissa
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2016
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-016-0180-2

Other articles of this Issue 1/2016

Diabetology & Metabolic Syndrome 1/2016 Go to the issue